Oncolytics Announces Publication Of Preclinical Research. BioSante Closes $48.0 Million Public Offering Of Common Stock. Print E-mail
By Staff and Wire Reports   
Tuesday, 02 August 2011 19:25
Below is a look at some of the headlines for companies that made news in the healthcare sector on August 2, 2011.

Oncolytics Biotech Inc.  (NASDAQ:ONCY) announced an international team of researchers have reported on a study in the online version of Molecular Therapy, a publication of The American Society of Gene and Cell Therapy, investigating the timing of chemotherapy delivery that optimizes the efficacy of systemic REOLYSIN.

The paper is entitled Precise Scheduling of Chemotherapy Primes VEGF-producing Tumors for Successful Systemic Oncolytic Virotherapy, authored by Kottke et al. The report describes when to administer taxanes with reovirus to optimize viral delivery to the tumor mass.

The researchers demonstrated that this drug combination was superior to either treatment alone, and were able to reproducibly cure nearly half of the treated animals by employing this optimized schedule of paclitaxel/REOLYSIN.

---

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX)
announced the closing of its underwritten public offering of 16.0 million shares of common stock at a public offering price of $3.00 per share, for total gross proceeds of $48.0 million before underwriting discounts and commissions. The offering resulted in net proceeds to BioSante of approximately $45.0 million. All of the shares in the offering were sold by BioSante.

BioSante has granted the underwriters a 30 day option to purchase up to an aggregate of 2.4 million additional shares of common stock at the same price to cover over-allotments, if any. BioSante anticipates using the net proceeds from the offering for general corporate purposes, including, without limitation, funding the ongoing Phase III clinical study program for LibiGel for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA).


Also Tuesday:


ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that MuGard, its lead product for oral mucositis, has been added to Humana's pharmacy benefit network.

Anadys Pharmaceuticals, Inc. (Nasdaq:ANDS) announced today that it will report second quarter 2011 financial results on Monday, August 8, 2011, after the U.S. financial markets close.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai Inc. announced today the completion of a clinical study that measured lorcaserin concentrations in human cerebrospinal fluid (CSF) and plasma and related data analyses.

BioSpecifics Technologies Corp. (NASDAQ:BSTC), a biopharmaceutical company developing first in class collagenase-based products, announced today that it will host a conference call and live audio webcast at 8:30am EDT on Tuesday, August 9, 2011 to report its second quarter 2011 financial results and corporate highlights.

Caliper Life Sciences, Inc. (NASDAQ:CALP) today reported its financial results for the second quarter ended June 30, 2011.  

Cambrex Corporation (NYSE:CBM) reports second quarter results for the period ended June 30, 2011.

CANTEL MEDICAL CORP. (NYSE:CMN), through its Minntech subsidiary, has acquired the business and substantially all of the assets of Byrne Medical, Inc.

Cephalon, Inc. (Nasdaq:CEPH) today reported second quarter 2011 net sales of $730.1 million, a 2 percent increase compared to net sales of $712.4 million for the second quarter of 2010.  

Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) is pleased to provide its shareholders with a corporate update of developments that have been achieved since the appointment of Mark Fletcher as President & Chief Executive Officer on September 29, 2010.

GenVec, Inc. (Nasdaq:GNVC) will report financial results for the second quarter of 2011 on Tuesday, August 9, 2011, before the U.S. financial markets open.

Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, and its subsidiary, BioMarCare Technologies Ltd. ("BioMarCare") announced that the prestigious Binational Industrial Research and Development (BIRD) Foundation has given initial approval for a $900,000 grant for a joint project for BioMarCare and Ariadne Inc. to develop a diagnostic colorectal cancer test.

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) announced today that an international team of researchers has reported on a study in the online version of Molecular Therapy, a publication of The American Society of Gene and Cell Therapy, investigating the timing of chemotherapy delivery that optimizes the efficacy of systemic REOLYSIN®.

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2011.

Techne Corporation's (NASDAQ:TECH) financial results for the fourth quarter and fiscal year ended June 30, 2011 include the following highlights:  Fourth quarter earnings grew 9.4% to $28.3 million or $.76 per diluted share.  

Verenium Corporation (Nasdaq:VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it will release 2011 second quarter financial results on Tuesday, August 9, 2011 after market close.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter